Literature DB >> 24323065

[What can colorectal cancer centers achieve in the diagnostics and therapy of colorectal liver metastases?].

S Wesselmann1, T Seufferlein.   

Abstract

Successful resection of liver metastases increases overall survival and can even be a curative approach in patients with colorectal cancer (CRC) and isolated liver metastases. Resection of liver metastases has clearly changed the therapy of this group of patients and has become a standard procedure that is being used increasingly more. Accordingly, liver metastasis resection has been included in the German evidence-based guidelines and also in international guidelines on the treatment of CRC. The treatment of colorectal liver metastases requires a multidisciplinary team of experts in the disease, including experienced radiologists, medical oncologists, radiotherapists, pathologists and surgeons. The interdisciplinary approach to the treatment in specialized tumor boards staffed by qualified experts is a prerequisite for successful certification as a colorectal cancer center by the German Cancer Society. Regular audits ensure that these requirements and that defined quality indicators regarding the tumor board and primary and secondary liver metastasis resection, are fulfilled. The certification system of the colorectal cancer centers requires and promotes conditions that allow an optimal and guideline-oriented treatment of colorectal liver metastases both at the level of personnel and infrastructure of a given center. The high primary and secondary resection rates in these centers testify that the multidisciplinary teams are effective. A detailed analysis of the audit reports reveals the close collaboration of all partners within the certified networks. These networks also comprise external cooperation with highly specialized hospitals if and when necessary. However, the annual report of the certificated colorectal cancer centers also demonstrates areas for further improvements in multidisciplinary cooperation.

Entities:  

Mesh:

Year:  2014        PMID: 24323065     DOI: 10.1007/s00104-013-2562-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  9 in total

1.  [S3-guideline colorectal cancer version 1.0].

Authors:  C Pox; S Aretz; S C Bischoff; U Graeven; M Hass; P Heußner; W Hohenberger; A Holstege; J Hübner; F Kolligs; M Kreis; P Lux; J Ockenga; R Porschen; S Post; N Rahner; A Reinacher-Schick; J F Riemann; R Sauer; A Sieg; W Scheppach; W Schmitt; H J Schmoll; K Schulmann; A Tannapfel; W Schmiegel
Journal:  Z Gastroenterol       Date:  2013-08-16       Impact factor: 2.000

2.  Epidemiology and management of liver metastases from colorectal cancer.

Authors:  Sylvain Manfredi; Côme Lepage; Cyril Hatem; Olivier Coatmeur; Jean Faivre; Anne-Marie Bouvier
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

3.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Authors:  Stéphane Benoist; Antoine Brouquet; Christophe Penna; Catherine Julié; Mostafa El Hajjam; Sophie Chagnon; Emmanuel Mitry; Philippe Rougier; Bernard Nordlinger
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

4.  Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.

Authors:  Dietmar Tamandl; Markus Klinger; Sandra Eipeldauer; Beata Herberger; Klaus Kaczirek; Birgit Gruenberger; Thomas Gruenberger
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

5.  Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?

Authors:  René Adam; Robbert J de Haas; Dennis A Wicherts; Thomas A Aloia; Valérie Delvart; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

6.  Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

Authors:  René Adam; Dennis A Wicherts; Robbert J de Haas; Oriana Ciacio; Francis Lévi; Bernard Paule; Michel Ducreux; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

7.  Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Thomas A Aloia; Steven A Curley; Giuseppe Zimmitti; Steven H Wei; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2013-02-03       Impact factor: 5.344

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.